In breast cancer, TXNIP knockdown increased Ki-67 expression (a marker of cell proliferation) and decreased p27 (a cell cycle regulatory protein), leading to enhanced breast cancer cell growth in vitro and in vivo (64–66). The gene discussed is TXNIP; the disease is breast carcinoma.